Burning Rock Biotech Limited (BNR) Announces Proposed 1.838M ADS Secondary Offering

Burning Rock Biotech Limited (NASDAQ: BNR), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a public secondary offering by certain selling shareholders (the “Offering”) of 1,838,000 American Depositary Shares (“ADSs”), each representing one Class A ordinary share of the Company. The selling shareholders have granted the underwriters an option, exercisable within 30 days from the date of the final prospectus, to purchase up to 275,700 additional ADSs.

The Company will not receive any proceeds from the sale of the ADSs by the selling shareholders.

Morgan Stanley & Co. LLC, BofA Securities, Inc. and Cowen and Company, LLC are acting as joint bookrunners for the Offering.

You May Also Be Interested In

• Fisker (FSR) files form 10-K, sees more job cuts, reiterates going concern doubts
• Exicure Inc. (XCUR) Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
• Advent Technologies (ADN) Receives Nasdaq Notice on Late Filing of its Form 10-K